<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905890</url>
  </required_header>
  <id_info>
    <org_study_id>QA906</org_study_id>
    <nct_id>NCT02905890</nct_id>
  </id_info>
  <brief_title>The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis</brief_title>
  <acronym>HCBV</acronym>
  <official_title>Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MRC/UVRI Uganda Research Unit on Aids</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study, Hormonal Contraception &amp; BV (HCBV), will investigate the effect of NET-EN
      and DMPA on recurrent BV, vaginal microbiota and inflammatory markers among women at high
      risk for HIV in Kampala, Uganda. The hypothesis is that NET-EN will show a similar beneficial
      effect on recurrent BV and vaginal microbiota as DMPA, without inducing signs of mucosal
      inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial vaginosis (BV) is highly prevalent among women in Africa and is associated with HIV
      acquisition. BV has been described as a dysbiosis, or a microbial imbalance, and is treated
      with metronidazole; however, once treated, it often recurs rapidly. Developing robust
      treatment strategies to prevent recurrent BV is important for HIV prevention in key
      populations at high risk for HIV infection.

      There is evidence that hormonal contraceptives, including depot medroxyprogesterone acetate
      (DMPA), decrease BV recurrence; however, there is also evidence that DMPA increases the risk
      of HIV infection. Encouraging women to start or switch to an alternative progestin injectable
      such as norethisterone enantate (NET-EN) may mitigate HIV risk whilst decreasing the risk of
      recurrent BV. To date, there are no published studies that have investigated the effect of
      NET-EN on vaginal microbiota.

      The proposed study will investigate the effect of NET-EN and DMPA on recurrent BV, vaginal
      microbiota and inflammatory markers among women at high risk for HIV in the Good Health for
      Women Project in Kampala, Uganda. Consenting and eligible women will be treated for BV, and
      randomised to either NET-EN plus condoms or condoms only. Women currently using DMPA will be
      enrolled as an observational comparison arm. All participants will be interviewed and
      examined; samples for vaginal microbiota, sexually transmitted infections, and inflammatory
      markers will be obtained. Women will be followed up after 1 week, and 1, 2, 3, 4 and 6
      months. The primary outcomes will be differences in vaginal microbiota clusters, time to
      recurrent BV, and inflammatory markers. Qualitative research will be carried out to assess
      the acceptability of, and adherence to, NET-EN.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to diagnosis of recurrent BV</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportional of participants with Lactobacillus-dominant cluster</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of markers for inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>Twenty-four soluble immune proteins will be quantified by in-house multiplex bead immunoassay including interleukin(IL)-1α, IL1β, IL-2, IL4, IL-6, IL-7, IL- 8, IL-12, IL-15, IL16, IFN-g, MIP-1β, SDF1β, TNF-α, IP-10, RANTES, GM-CSF, G-CSF, MIG, IFN- -β, TGF-β, MCP-1, MCP-2, MIP-3α and other immune proteins as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of norethisterone enanthate as measured by qualitative interviews</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Norethisterone enanthate plus condoms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg Norethisterone enanthate intramuscularly every eight weeks at enrolment, 2 and 4 months. Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Condoms only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethisterone enantate</intervention_name>
    <description>Noristerat® 200mg, solution for intramuscular injection given every 8 weeks</description>
    <arm_group_label>Norethisterone enanthate plus condoms</arm_group_label>
    <other_name>Noristerat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Condoms</intervention_name>
    <description>Latex male condoms</description>
    <arm_group_label>Norethisterone enanthate plus condoms</arm_group_label>
    <arm_group_label>Condoms only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BV positive by Nugent score

          -  HIV negative

          -  Capable of providing written informed consent

        Exclusion Criteria:

          -  Currently pregnant or using a reliable contraception (e.g. injectables, intrauterine
             devices, implant, oral contraceptive pills)

          -  Desiring pregnancy in the next year

          -  History of tubal ligation or hysterectomy

          -  Contraindication to progestin-only contraceptives

          -  Unable to comprehend consent material because of language barrier or psychological
             difficulty
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanna C Francis, MSc MPH PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suzanna C Francis, MSc MPH PHD</last_name>
    <phone>+44 0207 927 2245</phone>
    <email>suzanna.francis@lshtm.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Harman</last_name>
    <phone>+44 0207 927 2483</phone>
    <email>Sarah.Harman@lshtm.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MRC/UVRI Mengo Clinic and Research Station</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Seeley, PhD</last_name>
      <email>Janet.Seeley@lshtm.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Yunia Mayanja, MD</last_name>
      <email>Yunia.Mayanja@mrcuganda.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Mitchell C, Marrazzo J. Bacterial vaginosis and the cervicovaginal immune response. Am J Reprod Immunol. 2014 Jun;71(6):555-63. doi: 10.1111/aji.12264. Review.</citation>
    <PMID>24832618</PMID>
  </reference>
  <reference>
    <citation>Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006 Jun 1;193(11):1478-86. Epub 2006 Apr 26.</citation>
    <PMID>16652274</PMID>
  </reference>
  <reference>
    <citation>Francis SC, Looker C, Vandepitte J, Bukenya J, Mayanja Y, Nakubulwa S, Hughes P, Hayes RJ, Weiss HA, Grosskurth H. Bacterial vaginosis among women at high risk for HIV in Uganda: high rate of recurrent diagnosis despite treatment. Sex Transm Infect. 2016 Mar;92(2):142-8. doi: 10.1136/sextrans-2015-052160. Epub 2015 Aug 7.</citation>
    <PMID>26253744</PMID>
  </reference>
  <reference>
    <citation>Vodstrcil LA, Hocking JS, Law M, Walker S, Tabrizi SN, Fairley CK, Bradshaw CS. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS One. 2013 Sep 4;8(9):e73055. doi: 10.1371/journal.pone.0073055. eCollection 2013. Review.</citation>
    <PMID>24023807</PMID>
  </reference>
  <reference>
    <citation>Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis - striving for long-term cure. BMC Infect Dis. 2015 Jul 29;15:292. doi: 10.1186/s12879-015-1027-4. Review.</citation>
    <PMID>26219949</PMID>
  </reference>
  <reference>
    <citation>Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, Delany-Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S, Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-Jones D, van de Wijgert JH, Stalter R, Low N. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med. 2015 Jan 22;12(1):e1001778. doi: 10.1371/journal.pmed.1001778. eCollection 2015 Jan.</citation>
    <PMID>25612136</PMID>
  </reference>
  <reference>
    <citation>Govender Y, Avenant C, Verhoog NJ, Ray RM, Grantham NJ, Africander D, Hapgood JP. The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor. PLoS One. 2014 May 19;9(5):e96497. doi: 10.1371/journal.pone.0096497. eCollection 2014.</citation>
    <PMID>24840644</PMID>
  </reference>
  <reference>
    <citation>Morrison C, Fichorova RN, Mauck C, Chen PL, Kwok C, Chipato T, Salata R, Doncel GF. Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):109-17. doi: 10.1097/QAI.0000000000000103.</citation>
    <PMID>24413042</PMID>
  </reference>
  <reference>
    <citation>Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS. 2013 Jan 2;27(1):105-113. doi: 10.1097/QAD.0b013e32835a5a52.</citation>
    <PMID>23014519</PMID>
  </reference>
  <reference>
    <citation>Devoize JL, Sztark G, Mehou-Loko A, Foo Cheung L, Joyes B. [Neurological manifestation of multiple cholesterol embolization syndrome: Value of MRI diffusion sequence]. Rev Neurol (Paris). 2013 Nov;169(11):913-6. doi: 10.1016/j.neurol.2012.11.006. Epub 2013 Mar 21. French.</citation>
    <PMID>23523018</PMID>
  </reference>
  <reference>
    <citation>Draper BH, Morroni C, Hoffman M, Smit J, Beksinska M, Hapgood J, Van der Merwe L. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005214. Review.</citation>
    <PMID>16856087</PMID>
  </reference>
  <reference>
    <citation>Polis CB, Curtis KM, Hannaford PC, Phillips SJ, Chipato T, Kiarie JN, Westreich DJ, Steyn PS. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS. 2016 Nov 13;30(17):2665-2683. Review.</citation>
    <PMID>27500670</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
    <mesh_term>Norethindrone enanthate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymised data from consenting participants will be made available to third parties in line with Open Access data requirements after a period of exclusive use by the study investigators</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

